Atopic Dermatitis as a Paradoxical Effect of Secukinumab for the Treatment of Psoriasis

In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been shown to be effective and safe in several studies. Their side effects are...

Full description

Saved in:
Bibliographic Details
Published in:Case reports in dermatology 2021-07, Vol.13 (2), p.336-339
Main Authors: Mendes Roncada, Eduardo V., Brambilla, Victoria Romanini, Freitas Filitto, Beatriz, Genta, Mariana Pirajá, Morgado de Abreu, Marilda Ap. M.
Format: Article
Language:English
Subjects:
atopic dermatitis
Case reports
Cytokines
Dermatitis
Drug dosages
Eczema
Immunoglobulins
Monoclonal antibodies
paradoxical effect
Psoriasis
secukinumab
Single Case
Citations: Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In the therapeutic arsenal to treat moderate to severe psoriasis, the new agents are secukinumab and ustekinumab, which are fully human monoclonal antibodies, directed against IL-17A and IL-12/23, respectively, which have been shown to be effective and safe in several studies. Their side effects are rare, and the most frequently reported side effects were infection, especially nasopharyngitis, headache, pruritus, high blood pressure, and low back pain. Unlike the side effects, the paradoxical reaction can be defined by the appearance or exacerbation of a pathological condition that usually responds to a certain class of drug. The appearance of this reaction in patients using anti-interleukins is poorly described; however, as they are new drugs, they may be more common than the literature reports. We describe a case of a paradoxical reaction, with the appearance of atopic dermatitis, after using secukinumab to treat psoriasis.
ISSN:1662-6567
1662-6567
DOI:10.1159/000513467